FDA Investigator Deborah Schmiel, PhD
Deborah Schmiel, PhD has conducted inspections on 4 sites in 3 countries as of 19 Jun 2024. See below for a list of the FDA enforcement documents resulting from those inspections.
Investigator Details
Number of Inspected Sites:
4
Last Inspection Date:
19 Jun 2024
Investigator Role:
FDA Investigation Participant
Redica ID:
Countries of Inspections:
Korea (Republic of),
Austria,
Denmark
FDA Investigators that have inspected at least one site in common with Deborah Schmiel, PhD:
Alicia M Mozzachio,
Anjali Shukla, PhD,
Bo Chi, PhD,
Brandon C Heitmeier,
Brian M Janelsins, PhD,
Carla J Lundi,
Christopher Downey, PhD,
Dennis Cantellops Paite,
Diane L Raccasi,
Dogbeda F Mackenzie,
Dr. Ralph M Bernstein, PhD,
Ephrem Hunde, PhD,
Hyung Yul Lee,
Jacek Cieslak, PhD,
Jeffrey P Raimondi,
Jennifer M Gogley,
Laura Fontan, MS,
Laurel A Beer,
Linda F Murphy,
Lucila B Nwatu,
Madushini Dharmasena, PhD,
Maria Gutierrez Lugo, PhD,
Maria Joselopez Barragan, PhD,
Marion Michaelis,
Marjorie A Shapiro, PhD,
Maryam Tabatabaie,
Matthew B Casale,
Michael Shanks, MS,
Monica Markovski, PhD,
Mra B Kamberem,
Mra V Millarw,
Patrick J Lynch,
Paul L Bellamy,
Peter Adams, PhD,
Phillip Angart, PhD,
Prabhu P Raju,
Rashmi Rawat, PhD,
Rebecca Rodriguez,
Reyes Candau Chacon, PhD,
Riley C Myers, PhD,
Sarah Arden,
Sarah Kennett, PhD,
Scott R Nichols, PhD,
Steven Fong, MS, PhD,
Thuy T Nguyen, LCDR,
Virginia Carroll, PhD,
Wayne E Seifert,
William Hallett, PhD,
Xianghong Jing (Emily), PhD,
Xiaoping Guan,
Yehualashet A Gessesse,
Yun Wu, PhD,
Zhong Li, PhD
Deborah Schmiel, PhD's Documents
Publish Date | Document Type | Title |
---|---|---|
June, 2016 | FDA 483 | Samsung Biologics Co., Ltd. - Form 483, 2016-06-22 |
October, 2019 | FDA 483 | FUJIFILM Diosynth Biotechnologies Denmark ApS - Form 483, 2019-10-11 |
February, 2018 | FDA 483 | Sandoz GmbH - Form 483, 2018-02-20 |
June, 2018 | FDA 483 | Samsung Biologics Co., Ltd. - Form 483, 2018-06-26 |
Experience Redica Systems’ NEW investigator profiles and dashboards
Redica Systems customers get access to over 1,400 FDA Investigator profiles, containing powerful analysis like:
- Total inspections conducted
- 483 rate
- OAI rate
- Warning Letter rate
- Inspections by Industry, Scope, and Inspection Reason
- And much more
Investigator Profiles are not sold as on-demand documents. If you’d like to see one, fill out the form below to connect with our Sales Team and get it in your inbox as little as 24 hours.
![FDA Investigator Profile Icon](https://redica.com/document-store/images/InspectorProfile.png)
Talk to sales to access our investigator profiles
Loading...
Investigator Profiles Are Just the Tip of the Iceberg
Becoming a Redica Systems customer not only provides you with unlimited access to profiles similar to the one above for every current and former FDA Investigator, but also grants you access to:
Inspection Intelligence
- Pre-Approval Inspection (PAI) trends
- The ability to filter nearly any FDA enforcement action by GxP labels like GMP, GCP, etc.
- Latest 483s: see what the trends are across all FDA Investigators
- CFR Heatmap: Citations aggregated by Subpart by Year
Vendor Intelligence
- Full inspection histories for your vendors down to the specific site level
- All of the functionality mentioned above but isolated to just your vendors
Regulatory Intelligence
- Zero in on the trends for a specific agency/regulator (ex. FDA, MHRA, EMA, Health Canada)
- All the latest "Signals" from agencies around the world, segmented by Country, Type (ex. Guidance, Decree...), Category (ex. Rules/Regulations/Guidance, News, Reports...), Theme (ex. Cell and Gene Therapy, AI...), and more